Click Therapeutics Raises $50M Series D to Advance FDA-Validated Digital Therapeutics for Schizophrenia

Quiet capital tends to be the most dangerous kind. No theatrics, no victory laps, just a deliberate move that changes leverage across the board. That is exactly how Click Therapeutics stepped back into the conversation, locking in a $50M Series D from Boehringer Ingelheim and tightening its grip on where digital therapeutics actually go next.

David Benshoof Klein, Founder and CEO, alongside Han Chiu, CTO, have been building in a lane most people talked about but never really touched. Prescription digital therapeutics is easy to pitch, hard to prove, and even harder to scale without credibility. Click Therapeutics did not chase attention, they chased evidence. There is a difference, and the market can feel it.

Since 2012, the company has been working a thesis that sounds simple until you try to operationalize it. If behavior and cognition sit at the core of many diseases, then software should not just support treatment, it should be treatment. Not adjacent, not optional, but prescribed. That idea has been floating around for years, but Click Therapeutics treated it like infrastructure, not a feature.

CT-155 is where that philosophy gets real. An investigational digital therapeutic targeting schizophrenia, specifically the negative symptoms that quietly dismantle quality of life. The CONVOKE Phase III trial delivered statistically significant improvement in those symptoms, which moves this out of concept territory and into clinical relevance. In a market flooded with dashboards and engagement metrics, this is outcomes talking.

Boehringer Ingelheim did more than invest. They restructured the relationship, handing Click Therapeutics full commercial control of CT-155 pending regulatory clearance. That is not standard operating procedure. That is conviction. In the startup ecosystem, when a global pharma player transfers that level of responsibility, it signals belief not just in a product, but in a platform and the team behind it.

A pattern is forming that is hard to ignore. Capital is no longer chasing potential alone, it is chasing proof that survives regulatory friction. Click Therapeutics did the slow work. Clinical validation, FDA pathways, real endpoints. No shortcuts, no theater. Just disciplined execution over time, which is starting to look like the only reliable moat left.

If you are building in this space, the takeaway is not just about digital therapeutics. It is about how credibility is earned when the stakes are high. The startup ecosystem rewards speed until it doesn’t, and then it rewards truth. Click Therapeutics chose the second path early, and now the market is catching up.